BaseSpace
Correlation
Engine-Public
Sign In
Register
Correlation Engine 2.0
Home
My Data
Bookmarks
Collaborations
Inbox
Import Your Data
QuickView
FAQ
What is QuickView?
What can my QuickView results tell me?
What are the sources for the General Info tab in QuickView?
More QuickView FAQs
Back to top
QuickView
Curated
Studies
Body
Atlas
Disease
Atlas
Pharmaco
Atlas
Knockdown
Atlas
Genetic
Markers
Pathway
Enrichment
Literature
Clinical
Trials
0
Meta-
Analysis
QuickView
Search sequence regions
(e.g.
Lung
,
Hematopoietic cell
,
Rosiglitazone
,
rs4950928
,
IGF1
,
Apoptosis
,
Allergy to pollen
)
Organisms
Chromosomes
Start
Stop
Homo Sapiens
Mus Musculus
Rattus Norvegicus
C. Elegans
D. Melanogaster
Saccharomyces Cerevisiae
QuickView
Go back to main search
Bookmark
Forward
QuickView
for
extracellular signal- regulated kinases
Summary
General Info
Curated Studies
Most Correlated Studies
L1000 CMAP - Amelanotic malignant melanoma of skin A375 cells treated with ligand perturbagens
L1000 CMAP - Colorectal cancer HT29 cells treated with ligand perturbagens
L1000 CMAP - Prostate carcinoma VCaP cells treated with ligand perturbagens
L1000 CMAP - Lung cancer A549 cells treated with ligand perturbagens
L1000 CMAP - Adenocarcinoma of breast MCF7 cells treated with ligand perturbagens
Explore Curated Studies Results
Literature
Most Relevant Literature
Distinct binding modes of a benzothiazole derivative confer structural bases for increasing ERK2 or …
Linear motif specificity in signaling through p38α and ERK2 mitogen-activated protein kinases.
Low entropic cost of binding confers high selectivity on an allosteric ERK2 inhibitor.
Targeting MAPK in Cancer 2.0.
MAPK signaling pathway orchestrates and fine-tunes the pathogenicity of Colletotrichum falcatum.
Explore Literature Results
Clinical Trials
Most Relevant Clinical Trials
A Multicentre, Open Label, Phase 1 Trial in Japan of the Mitogen Activated Protein Extracellular Sig…
A Study to Evaluate the Effect of Lipid Infusion on Toll Like Receptor 4 (TLR4) Signaling
Randomized Phase II Study of AZD6244 (Mitogen-activated Protein Kinase Inhibitor) MEK-Inhibitor With…
Vemurafenib Neoadjuvant Trial in Locally Advanced Thyroid Cancer
Sorafenib for Patients With Metastatic or Recurrent Esophageal and Gastroesophageal Junction Cancer
Explore Clinical Trials Results
search
→
result
search
→
result
See more about this page
See complete FAQ